A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors
This study has been completed.
Merck Sharp & Dohme Corp.
First Posted: August 31, 2001
Last Update Posted: December 9, 2005
Information provided by:
NIH AIDS Clinical Trials Information Service